Experienced in Rhizomelic Pseudopolyarthritis

Philippe Guilpain

Montpellier, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Rhizomelic Pseudopolyarthritis
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Philippe Guilpain practices in Montpellier, France. Mr. Guilpain is rated as an Experienced expert by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. His top areas of expertise are Vasculitis, Scleroderma, Systemic Sclerosis (SSc), and Granulomatosis with Polyangiitis.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Rhizomelic Pseudopolyarthritis.

Gender
Male

Locations

Montpellier, France
Other Locations
CH de Melun
Melun, France
Paris, France
Nimes, 30029, France
CHU Lille
Lille, France
Roussillon-en-morvan, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Enrollment Status: Recruiting
Publish Date: September 26, 2024
Intervention Type: Drug
Study Drug: Itacitinib
Study Phase: Phase 2
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: March 04, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trial

107 Total Publications

Correction: Neurological manifestations in patients with VEXAS syndrome.
Correction: Neurological manifestations in patients with VEXAS syndrome.
Journal: Journal of neurology
Published: May 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guilpain's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile